이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 파킨슨병 환자에서 레시곤의 효과 및 안전성에 관한 장기관찰연구 (ELEGANCE)

2026년 10월 1일 업데이트: Britannia Pharmaceuticals Ltd.

ELEGANCE - 일상적인 치료에서 진행된 파킨슨병 환자를 대상으로 한 Levodopa-Entacapone-Carbidopa Intestinal Gel(Lecigon®)의 장기적 효과 및 안전성에 대한 비간섭 연구

This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).

Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.

In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

Study design:

Non-interventional study, primary data collection.

No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.

The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.

The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.

Primary Objectives:

  • Long-term effectiveness of Lecigon®
  • Long-term safety of Lecigon®

Secondary Objectives:

  • Patient non-motor symptoms and quality of life
  • Healthcare resource utilisation by patients

연구 유형

관찰

등록 (실제)

312

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Groningen, 네덜란드, 97139713
        • University Medical Center Groningen
      • Copenhagen, 덴마크, 2400
        • Bispebjerg Hospital
      • Bad Segeberg, 독일, 23795
        • Segeberger Kliniken GmbH Neurologisches Zentrum
      • Beelitz-Heilstätten, 독일, 14547
        • Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
      • Berlin, 독일, 10117
        • Charité - Universitätsmedizin Berlin
      • Cologne, 독일
        • Uniklinik Köln
      • Coppenbrügge, 독일, 31863
        • Krankenhaus Lindenbrunn
      • Essen, 독일, 45147
        • Klinik für Neurologie - Universitätsklinikum Essen
      • Freiburg im Breisgau, 독일, 79106
        • Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
      • Göttingen, 독일, 37075
        • Zentrum für Seltene Erkrankungen Göttingen
      • Marburg, 독일, 35043
        • Universitätsklinikum Giessen und Marburg
      • Oldenburg, 독일, 26122
        • Evangelisches Krankenhaus Oldenburg
      • Osnabrück, 독일, 49076
        • Klinikum Osnabrück GmbH Klinik für Neurologie
      • Tübingen, 독일, 72076
        • Universitätsklinikum Tübingen
      • Ulm, 독일, 89081
        • RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
      • Wolfach, 독일, 77709
        • Parkinson-Klinik Ortenau
      • Brasov, 루마니아, 500326
        • Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
      • Bucharest, 루마니아, 050098
        • Bucharest University Emergency Hospital
      • Bucharest, 루마니아
        • Fundeni Clinical Institute
      • Bucharest, 루마니아, 011461
        • Spitalul Universitar de Urgență Elias
      • Bucharest, 루마니아, 020125
        • Colentina Hospital Bucharest
      • Cluj-Napoca, 루마니아, 400347
        • County Emergency Hospital Cluj-Napoca
      • Constanța, 루마니아, 900591
        • County Clinical Emergency Hospital of Constanta
      • Timișoara, 루마니아, 300723
        • Timiş County Emergency Clinical Hospital- Neurology 1
      • Timișoara, 루마니아, 300723
        • Timiş County Emergency Clinical Hospital
      • Târgu Mureş, 루마니아, 540136
        • Emergency County Hospital Targu Mures
      • Bruges, 벨기에, 8000
        • AZ Sint-Jan
      • Edegem, 벨기에, 2650
        • Antwerp University Hospital
      • Ghent, 벨기에
        • Ghent University Hospital
      • Liège, 벨기에
        • University Hospital Liege
      • Tournai, 벨기에, 7500
        • Centre Hospitalier de Wallonie picarde (Chwapi)
      • Sofia, 불가리아, 1113
        • Sveti Naum
      • Gothenburg, 스웨덴, 413 45
        • Sahlgrenska University Hospital
      • Lund, 스웨덴
        • Skånes universitetssjukhus Lund
      • Uppsala, 스웨덴, 751 85
        • Uppsala university hospital
      • Barcelona, 스페인, 08025
        • Hospital de la Santa Creu i Sant Pau
      • Madrid, 스페인, 28040
        • Hospital Clínico San Carlos
      • Madrid, 스페인, 28034
        • Hospital Universitario Ramón y Cajal
      • Madrid, 스페인
        • Hospital de la Princesa
      • Seville, 스페인, 41013
        • Hospital Virgen del Rocio
      • Ljubljana, 슬로베니아, 1000
        • Department of Neurology, University Medical Centre
      • Maribor, 슬로베니아, 2000
        • Univerzitetni klinični center Maribor
      • Dublin, 아일랜드, D07 R2WY
        • The Dublin Neurological Institute, Mater Hospital
      • Dublin, 아일랜드, D04 T6F4
        • St. Vincent's University Hospital
      • Graz, 오스트리아, 8036
        • Universitätsklinik für Neurologie, Medizinische Universität Graz
      • Hermagor, 오스트리아, 9620
        • Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
      • Innsbruck, 오스트리아, 6020
        • Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
      • Linz, 오스트리아, 4020
        • Kepler Universitätsklinikum
      • Brno, 체코
        • Masaryk university
      • Olomouc, 체코
        • Fakultní nemocnice Olomouc
      • Osijek, 크로아티아, 31000
        • UHC Osijek, J. Klinici za neurologiju
      • Rijeka, 크로아티아
        • University Hospital Centre Rijeka (KBC Rijeka)
      • Zagreb, 크로아티아, 10000
        • University Hospital Centre (KBC Zagreb)
      • Zagreb, 크로아티아, 10000
        • Klinička bolnica Dubrava
      • Budapest, 헝가리
        • Semmelweis Egyetem Neurológiai Klinika Budapest
      • Pécs, 헝가리, 7623
        • Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
      • Szeged, 헝가리, 6725
        • SZTE Szent-Györgyi Albert Klinikai Közpon

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Treating physician's normal patient pool

설명

Inclusion Criteria:

  • Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
  • Patients or legal representative must have signed informed consent to participate in the study
  • Patients are not taking part in another clinical (interventional) study at the same time

Exclusion Criteria:

  • Patients with contraindications as defined in the current version of the SmPC for Lecigon®
  • Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
  • Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: OTHER

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications)

24 months
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living)

24 months
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses

24 months
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation

24 months
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected

24 months
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I)

24 months
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C)

24 months
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
기간: 24 months

To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item.

24 months
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
기간: 24 months

To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected

24 months

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS)

24 months
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2)

24 months
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living)

24 months
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39)

24 months
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit

24 months

기타 결과 측정

결과 측정
측정값 설명
기간
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
기간: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation

24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 7월 6일

기본 완료 (추정된)

2026년 10월 7일

연구 완료 (추정된)

2026년 10월 7일

연구 등록 날짜

최초 제출

2021년 7월 29일

QC 기준을 충족하는 최초 제출

2021년 9월 3일

처음 게시됨 (실제)

2021년 9월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다